{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T03:30:09Z","timestamp":1790220609587,"version":"4.1.0"},"reference-count":24,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Dermatology"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.clindermatol.2025.12.002","type":"journal-article","created":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T16:56:34Z","timestamp":1766422594000},"page":"294-298","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Equitable access to biologic therapies in a psoriasis safety-net clinic: A retrospective cohort study"],"prefix":"10.1016","volume":"44","author":[{"given":"Sammya","family":"Mufarrej","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franco","family":"Rongioletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Romanelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clindermatol.2025.12.002_bib0001","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1001\/jama.2020.4006","article-title":"Pathophysiology, clinical presentation, and treatment of psoriasis: a review","volume":"323","author":"Armstrong","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.clindermatol.2025.12.002_bib0002","first-page":"467","article-title":"Psoriasis as a systemic disease","volume":"121","author":"Mrowietz","year":"2024","journal-title":"Dtsch Arztebl Int"},{"key":"10.1016\/j.clindermatol.2025.12.002_bib0003","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1001\/jamadermatol.2023.5439","article-title":"Patient-reported outcome measures for health-related quality of life in patients with psoriasis: a systematic review","volume":"160","author":"P\u00e9rez-Chada","year":"2024","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.clindermatol.2025.12.002_bib0004","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1001\/jamadermatol.2013.5015","article-title":"Psoriasis severity and the prevalence of major medical comorbidity: a population-based study","volume":"149","author":"Yeung","year":"2013","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.clindermatol.2025.12.002_bib0005","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1111\/bjd.15885","article-title":"First-line systemic treatment of psoriasis: staying conventional or going biologic?","volume":"177","author":"Balak","year":"2017","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2025.12.002_bib0006","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1016\/j.jid.2024.09.012","article-title":"Curing psoriasis","volume":"144","author":"Lwin","year":"2024","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.clindermatol.2025.12.002_bib0007","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1007\/s13555-021-00511-1","article-title":"Comparative efficacy and relative ranking of biologics and oral therapies for moderate-to-severe plaque psoriasis: a network meta-analysis","volume":"11","author":"Armstrong","year":"2021","journal-title":"Dermatol Ther (Heidelb)"},{"key":"10.1016\/j.clindermatol.2025.12.002_bib0008","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.3390\/ijms21051690","article-title":"Efficacy and safety of biologics for psoriasis and psoriatic arthritis and their impact on comorbidities: a literature review","volume":"21","author":"Kamata","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.clindermatol.2025.12.002_bib0009","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1080\/09546634.2018.1466022","article-title":"Comparison of the cost-effectiveness of biologic drugs used for moderate-to-severe psoriasis treatment in the United States","volume":"29","author":"Wu","year":"2018","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.clindermatol.2025.12.002_bib0010","doi-asserted-by":"crossref","DOI":"10.7573\/dic.212266","article-title":"The cost of biologics for psoriasis is increasing","volume":"3","author":"Cheng","year":"2014","journal-title":"Drugs Context"},{"key":"10.1016\/j.clindermatol.2025.12.002_bib0011","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1001\/jamadermatol.2014.3593","article-title":"Economic burden of psoriasis in the United States: a systematic review","volume":"151","author":"Brezinski","year":"2015","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.clindermatol.2025.12.002_bib0012","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1001\/jamadermatol.2023.6236","article-title":"Use of efficiency frontiers to align prices and clinical benefits of biologic therapies for plaque psoriasis","volume":"160","author":"Egilman","year":"2024","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.clindermatol.2025.12.002_bib0013","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1111\/ijd.17236","article-title":"Disparities and barriers to the access of biologics in moderate-to-severe adult psoriasis","volume":"63","author":"Wan","year":"2024","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.clindermatol.2025.12.002_bib0014","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1007\/s00403-022-02410-7","article-title":"Equity in the usage of biologics for psoriasis in the working poor","volume":"315","author":"Eley","year":"2023","journal-title":"Arch Dermatol Res"},{"key":"10.1016\/j.clindermatol.2025.12.002_bib0015","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1001\/jamadermatol.2021.3616","article-title":"Out-of-pocket costs of specialty medications for psoriasis and psoriatic arthritis treatment in the Medicare population","volume":"157","author":"Pourali","year":"2021","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.clindermatol.2025.12.002_bib0016","unstructured":"Leeolou MC, Jia JL, Harris J, Liao W. The role of pharmacy benefit managers in access to biologics for dermatologic conditions. J Psoriasis Psoriatic Arthritis, in press."},{"key":"10.1016\/j.clindermatol.2025.12.002_bib0017","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.2147\/PPA.S326498","article-title":"Assessing the beneficial impact of a patient support program in secukinumab-treated patients with psoriasis in Italy","volume":"15","author":"Argenziano","year":"2021","journal-title":"Patient Prefer Adherence"},{"key":"10.1016\/j.clindermatol.2025.12.002_bib0018","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s40257-019-00498-8","article-title":"Psoriatic disease in the US Latino population: a comprehensive review","volume":"21","author":"Ashbaugh","year":"2020","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.clindermatol.2025.12.002_bib0019","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.jaad.2014.08.002","article-title":"A unique psoriasis biologics clinic serving underprivileged patients in the United States","volume":"72","author":"Romanelli","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2025.12.002_bib0020","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1007\/s40615-022-01282-x","article-title":"Exploring biologic treatment hesitancy among Black and Indigenous populations in Canada: a review","volume":"10","author":"Akuffo-Addo","year":"2023","journal-title":"J Racial Ethn Health Disparities"},{"key":"10.1016\/j.clindermatol.2025.12.002_bib0021","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1007\/s10067-014-2763-3","article-title":"Psoriasis and psoriatic arthritis in African American patients\u2013the need to measure disease burden","volume":"34","author":"Kerr","year":"2015","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.clindermatol.2025.12.002_bib0022","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1080\/09546634.2020.1820936","article-title":"Language proficiency and biologics access: a population study of psoriasis patients in the United States","volume":"33","author":"Chat","year":"2022","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.clindermatol.2025.12.002_bib0023","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1001\/jamadermatol.2024.5391","article-title":"Latine patients\u2019 beliefs, attitudes, and experience with psoriasis","volume":"161","author":"Gonzalez","year":"2025","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.clindermatol.2025.12.002_bib0024","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s40257-017-0332-7","article-title":"Psoriasis in skin of color: insights into the epidemiology, clinical presentation, genetics, quality-of-life impact, and treatment of psoriasis in non-white racial\/ethnic groups","volume":"19","author":"Kaufman","year":"2018","journal-title":"Am J Clin Dermatol"}],"container-title":["Clinics in Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0738081X25003359?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0738081X25003359?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T15:39:56Z","timestamp":1774712396000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0738081X25003359"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S0738081X25003359"],"URL":"https:\/\/doi.org\/10.1016\/j.clindermatol.2025.12.002","relation":{},"ISSN":["0738-081X"],"issn-type":[{"value":"0738-081X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Equitable access to biologic therapies in a psoriasis safety-net clinic: A retrospective cohort study","name":"articletitle","label":"Article Title"},{"value":"Clinics in Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clindermatol.2025.12.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}